Another risky one but with a new income stream things are looking up for Sun.
Why they did not perform better last year is anyones guess.
I suppose the big boys have been let down before but this time its different .
Take a look - long term holder.....

Might get there today!

Scorchio!

good day here

Muy scorchio!

Sorry - my mistake - interims were on the 14th LAST September. Still awaiting imminent RNS to give this years date!

(Gasps of horror!) ;o)

Sorry Kim :-) Some reasonable trades have gone through today. Close well above 12.

'S ok Skinny, I've got over the shock now! :o)

Another good sunny day!

24 August 2011

Surgical Innovations Group plc

("SI" or "the Group")

Notice of Results

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, will announce its results for the six months ended 30 June 2011 on Wednesday 14 September 2011.

An analyst presentation will take place at 9:30 am on 14 September 2011 at the offices of Seymour Pierce Limited, 20 Old Bailey, London, EC4M 7EN.

You were right in the end skinny! :o)

RNS Number : 3798N

Advanced Medical Solutions Grp PLC

01 September 2011

For immediate release: 1 September 2011

Advanced Medical Solutions Group plc

("AMS" or the "Company")

Development and Pre-Supply Agreement signed with Surgical Innovations Group plc

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that it has signed a Development and Pre-Supply Agreement ("the Agreement") with Surgical Innovations Group plc ("Surgical Innovations") (AIM: SUN), for the development and supply of a novel device for internal application of adhesives and sealants.

Under the terms of the Agreement, Surgical Innovations will develop and retain the intellectual property rights for a unique applicator to deliver accurately, individual drops of adhesive or sealant internally within the body, accessed via a minimally invasive surgical port site. In return for the exclusive rights to this applicator for the internal application of adhesives and sealants, AMS has agreed to purchase all of its requirements for the approved new applicator from Surgical Innovations for a period of ten years.

The development of the internal applicator is a key step in extending the Company's expertise in adhesives and sealants from purely topical applications to also addressing clinical needs inside the body. AMS has previously highlighted that the first target internal application would be the hernia mesh fixation market which is currently served by sutures, staples and tacks. This new internal applicator, together with the Company's adhesives, will allow AMS to address this important market with reduced surgical complications.

Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS said:

"This agreement combines our formulation and regulatory expertise with Surgical Innovations' applicator design and manufacturing expertise to introduce a new product to a global market for internal sealants that is now in excess of US$600 million. As we have previously indicated, an integral part of our tissue sealant and adhesives R&D is focused on moving our product range more towards the Operating Room, including internal applications. In this regard, we are optimistic that our partnership with Surgical Innovations will give us a market leading product, targeting the hernia mesh fixation market, which should be available for launch in 2013."

Graham Bowland, Chief Executive Office of Surgical Innovations added:

"Our agreement with AMS affirms SI's reputation in delivering leading design solutions to OEM customers. The applicator device for AMS is a natural extension to our existing minimally invasive surgical product portfolio and we have already commenced on the design work on a fully disposable device. As part of the agreement SI will retain the full intellectual property rights to the applicator device and will also manufacture it on behalf of AMS."

Half Yearly Report.

RNS Number : 1861O

Surgical Innovations Group PLC

14 September 2011


14 September 2011

Surgical Innovations Group plc

("SI" or "the Group")

Interim Results

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices for minimally invasive surgery ("MIS"), is pleased to announce its interim results for the six months ended 30 June 2011.

Financial highlights

-- Revenues of GBP3.20 million (H1 2010: GBP3.57 million)

-- Operating profit of GBP514,000 (H1 2010: GBP781,000)

-- Pre-tax profit of GBP474,000 (H1 2010: GBP766,000)

-- GBP1.36 million invested in manufacturing, research and development during the period

-- Gross margins in core MIS business increased to 42% (H1 2010: 35%)

-- Net cash of GBP594,000 generated from operating activities

-- Basic earnings per share of 0.12p (H1 2010: 0.18p)

Operational highlights

-- Current trading is encouraging with strong customer demand across the business

-- SI branded products up 29% to GBP2.05 million (H1 2010: GBP1.59 million)

-- Strong demand from OEM partners for R&D expertise

-- Increased penetration of Resposable(R) products will result in increased demand for high margin disposable parts going forward

-- Development of 3mm instrument range and devices for hip arthroscopy underway

-- Two major new product launches to take place in second half of the year: Pretzel-Flex(TM) and Optical Trocar for YelloPort+plus(R)

Skinny,

what do you think about SUN in light of the report?
DO you hold it?

ahoj - I sold back in June @10.1 having held for (ever) years. I keep watching as I think they are a good company, and will buy back at some point. They have had a reasonably good news flow recently and Graham Bowland seems credible. I believe there was an investor presentation this morning, so maybe worth seeing the outcome.

Surgical Innovations Group PLC

01 November 2011


For immediate release 1 November 2011

Surgical Innovations Group plc

("SI" or "the Group")

SI receives confirmation of successful RGF bid

Surgical Innovations Group (AIM: SUN), the designer and manufacturer of innovative medical devices, is pleased to announce that it has received confirmation from the Department of Business, Innovation and Skills, that it is one of 119 successful bids in the UK in the second round of the Government's GBP1.4 billion Regional Growth Fund.

The Regional Growth Fund (RGF) is a GBP1.4bn fund operating across England from 2011 to 2014. It supports projects and programs that lever private sector investment creating economic growth and sustainable employment. It aims particularly to help those areas and communities currently dependent on the public sector to make the transition to sustainable private sector-led growth and prosperity.

SI has received a conditional offer, subject to due diligence, which has been earmarked for job creation, apprenticeships, training, development of innovative medical devices and manufacturing infrastructure. The quantum of the funding to SI remains confidential at this stage of the process.

As part of the bid process, SI has committed to continue its own program of investment in the business, creating direct jobs and increasing the number of apprenticeships it offers over a three year period.

Commenting on this announcement, Graham Bowland, Chief Executive Officer of SI said:

"This is a significant boost for the Group and we are incredibly pleased that our bid has been successful. This funding will allow us to invest heavily in the business and its future growth through product innovation, manufacturing equipment and employment."

For more information on the Regional Growth Fund please visit: http://www.bis.gov.uk/policies/regional-economic-development/regional-growth-fund

- ends -

Mind the gap.

Surgical Innovations Group plc

("SI" or "the Group")

FDA Approval for Logic™ reusable instrument range

US contract with Premier healthcare alliance


Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of creative solutions for minimally invasive surgery, is pleased to announce that it is has received 510(k) clearance from the US Food and Drug Administration ("FDA") for its Logic™ range of reusable instruments and permits the use of the range in the US market.

The instruments are compatible with the Group's Logic™ Handles, which already have approval in the US, and are currently used with SI's Resposable™ Logi™Range.

Graham Bowland, Chief Executive Officer of the Group, said: "We are delighted to announce the FDA approval of our reusable instruments in the US. The economic drivers away from single use instruments in the US are clear, and our modular instruments are ideally positioned to satisfy current surgical procedure budgets."

The Group is also pleased to announce that its US master dealer, SI USA Inc., has been awarded a contract by the Premier healthcare alliance for the sale of the Group's Resposable™ Logi™Range, and Logic™ range of reusable instruments. The contract will run from 1 April 2012 for three years, with the option to extend a further two years upon the agreement of both parties.

The contract will provide SI with additional access to hospitals and hospital networks across the US, and replaces previous, but more limited, contracts already held with Premier.

Graham Bowland continued: "This latest contract with Premier provides us with much more flexibility in the products we can offer whilst giving us access to hospitals that we were previously unable to approach. This is a very exciting development for the Group and strengthens our position in our largest target market."

Seymour Pierce reiterates Buy TP 14.00p.

Seems fair enough!

RNS Number : 4309X
Surgical Innovations Group PLC
14 February 2012



14 February 2012
Surgical Innovations Group plc
("SI" or "the Group")

Issue of Equity

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that, following the exercise of options a Director and certain senior and former employees yesterday, it has issued and allotted 7,889,000 ordinary shares of 1p each.

Details of the Director's options exercised and resulting shareholding is as follows:-


Number of options
Exercise price
Total shareholding following issue
Total shareholding percentage of enlarged issued share capital
Graham Bowland,
Chief Executive
5,889,000
3,654,546 at 1.7p
2,234,454 at 3.5p
10,417,498
2.64%

Accordingly Application has been made to the London Stock Exchange for the 7,889,000 New Ordinary Shares of 1p each to be admitted to trading on AIM ("Admission"). It is expected that such Admission will occur at on 17 February 2012. The new ordinary shares rank pari passu with the existing shares of the Company.

Following Admission the total number of ordinary shares in issue will be 403,091,902 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the purposes of the Disclosure and Transparency Rules.

- Ends -
Enquiries:

Surgical Innovations Group plc
www.sigroupplc.com
Doug Liversidge, Non-Executive Chairman

Graham Bowland, Chief Executive Officer
Tel: +44 (0) 113 230 7597 or graham.bowland@surginno.co.uk